首页> 外文期刊>The Lancet >L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.
【24h】

L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.

机译:L1表达可预测子宫和卵巢癌患者的进展和生存。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Ovarian and uterine carcinomas are the most common cause of cancer-related deaths in gynecological malignant diseases. We aimed to assess whether the L1 adhesion molecule, an important mediator for cell migration for neural and tumour cells, is expressed in these carcinomas. METHODS: We investigated L1 expression by immunohistochemistry, RT-PCR, and Western blot analysis of tumour samples. Soluble L1 in the serum was detected by ELISA and immunoprecipitation. FINDINGS: We detected the L1 adhesion molecule in ovarian and uterine tumours in a stage-dependent manner. In a retrospective study L1 was found in 46 of 58 ovarian carcinomas and 20 of 72 uterine adenocarcinomas. L1 expression was an excellent predictor of poor outlook (p<0.00001). Patients with L1 positive uterine tumours were at high risk for progression even in the endometrioid-type tumours, which usually have a favourable prognosis. In uterine tumours, expression of L1 in curettage samples enabled us to identify aggressive tumoursbefore the operation. Soluble L1 was specifically detected in serum samples from patients with ovarian and uterine tumours. ADAM10, which was implicated in previous studies as L1 sheddase, was expressed in tumours in which soluble L1 was present in the serum. INTERPRETATION: L1 is overexpressed in ovarian and uterine carcinomas and is associated with short survival. L1 can serve as a new marker for prediction of clinical outcome and could be helpful to identify patients with uterine tumours who are at high risk for recurrent disease. L1 expression and cleavage could promote dissemination of tumours by facilitating cell migration.
机译:背景:卵巢癌和子宫癌是妇科恶性肿瘤中与癌症相关的死亡的最常见原因。我们旨在评估L1粘附分子(神经和肿瘤细胞的细胞迁移的重要介体)是否在这些癌症中表达。方法:我们通过免疫组化,RT-PCR和蛋白质印迹分析肿瘤样本来研究L1的表达。通过ELISA和免疫沉淀检测血清中的可溶性L1。结果:我们以阶段依赖的方式检测了卵巢和子宫肿瘤中的L1粘附分子。在一项回顾性研究中,在58例卵巢癌中的46例和72例子宫腺癌中的20例中发现了L1。 L1表达是不良前景的极佳预测指标(p <0.00001)。具有L1阳性子宫肿瘤的患者即使在通常预后良好的子宫内膜样肿瘤中也有发展的高风险。在子宫肿瘤中,刮除样品中L1的表达使我们能够在手术前鉴定出侵袭性肿瘤。在患有卵巢和子宫肿瘤的患者的血清样本中特异性检测到了可溶性L1。 ADAM10在以前的研究中被认为是L1脱氢酶,在血清中存在可溶性L1的肿瘤中表达。解释:L1在卵巢癌和子宫癌中过表达,与生存期短有关。 L1可以作为预测临床结局的新标志物,并且有助于识别患有复发性疾病高风险的子宫肿瘤患者。 L1的表达和切割可通过促进细胞迁移来促进肿瘤的扩散。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号